Degrader Pharmacokinetics and Modality Limits: Where the Patents Actually Sit
32.5% concentration at the top. The five most active assignees hold 981 of 3,016 records in scope — a third of the field sits with a handful of filers, not a long tail. Filings peaked in 2018 at 214 and have since settled into a lower, more stable band; the 2021-to-2024 comparison (153 to 129, a 16% decline) is the most reliable recent read, since later years are still being published.
- 1ARDELYX INC299
- 2ASTEX THERAPEUTICS LTD266
- 3UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION154
- 4KUMQUAT BIOSCIENCES INC141
- 5CANCER RESEARCH TECHNOLOGY LTD121
See the full degrader pharmacokinetics and modality limits analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on degrader pharmacokinetics patents
Why do degrader patents focus so heavily on pharmacokinetics rather than just target binding?
Degraders, particularly bifunctional molecules, routinely exceed classical rule-of-five limits on molecular weight and polar surface area, which caps oral bioavailability regardless of how potent the binding is. That has pushed a large share of recent claim activity toward molecular weight penalty, metabolic stability and formulation-enabling technology rather than target engagement alone. In this dataset, 79.9% of the 3,016 records in scope touch A61K medicinal-preparation claims, which is where much of this formulation and exposure work is captured.
Which companies lead in degrader pharmacokinetics patents?
The ranked assignee list returns 100 companies, with the leader holding 299 of the 3,016 records in scope and a fifth-place holder at 121. The top five assignees combined account for 981 records, or 32.5% of all records, showing real concentration at the top even though the ranking itself covers a broad set of academic, mid-cap and large-pharma filers. Individual identities and their exact standings are best read directly from the ranking table rather than summarised here, since positions shift as new records publish.
Is patent filing activity in this space slowing down?
Filings fell from 153 in 2021 to 129 in 2024, a 16% decline over the most recent three-year span that can be treated as complete. That is a real pullback but not a collapse, and it should not be read from 2025 or 2026 figures, since publication typically lags filing by about 18 months and those years are still filling in. The more informative signal is that several previously dominant assignees show zero filings in the latest tracked year, which is consistent with portfolio consolidation around established chemotypes.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Degrader Pharmacokinetics and Modality Limits covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.